Podcasts

Trastuzumab deruxtecan in the treatment of HER2-low metastatic breast cancer

Prof. Francois Duhoux and Prof. Mieke Van Bockstal (Cliniques universitaires St. Luc, Brussels)

 

NS ID XL-3966-Revision date 12/2023

This OncoTalk is brought to you by BJMO in partnership with AstraZeneca and Daiichi Sankyo.

References

Modi, S, et al. “Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer” N Engl J Med 2022; 387:9-20.

Tarantino, P. et al. “ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer” Annals of Oncology 2023; 34(8):645-659.

SUBSCRIBE TO BJMO ONCOTALKS SERIES